13. Life Quality Index Questionnaire: Observed Values at Visits 0, 6 and 12, Safety Population For quality of life analyses, a total of 7 paediatric patients aged between 8 and 16 completed the CHQ-PF50™ questionnaire at least once during the study. However, only three completed questionnaires at all three time points making any assessment of results unreliable. It was stated that after switching from their previous IgG treatment to Evogam, the majority of patients reported that they preferred home based SCIg treatment. Safety results Thirty-five patients were administered 1,111 infusions of Evogam and the mean number of infusions during the Treatment Period was 31.74. on infusions conducted at the study site, the total mean dose of Evogam was 73.23 g and the mean weekly dose of Evogam was 6.83 g. Treatment emergent adverse events Treatment emergent adverse events and events considered at possibly related to study treatment are summarised in Tables 14 and 15 below. Table 14. Study 05-23 Treatment-emergent Adverse Events Reported by > 10% of Total Patients, Safety Population
13. Life Quality Index Questionnaire: Observed Values at Visits 0, 6 and 12, Safety Population For quality of life analyses, a total of 7 paediatric patients aged between 8 and 16 completed the CHQ-PF50™ questionnaire at least once during the study. However, only three completed questionnaires at all three time points making any assessment of results unreliable. It was stated that after switching from their previous IgG treatment to Evogam, the majority of patients reported that they preferred home based SCIg treatment. Safety results Thirty-five patients were administered 1,111 infusions of Evogam and the mean number of infusions during the Treatment Period was 31.74. on infusions conducted at the study site, the total mean dose of Evogam was 73.23 g and the mean weekly dose of Evogam was 6.83 g. Treatment emergent adverse events Treatment emergent adverse events and events considered at possibly related to study treatment are summarised in Tables 14 and 15 below. Table 14. Study 05-23 Treatment-emergent Adverse Events Reported by > 10% of Total Patients, Safety Population